Connect with us

Hi, what are you looking for?

top
New analysis on AstraZeneca COVID-19 vaccine shows it increases immune responses to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants as a booster shot. /CFM

Capital Health

New AstraZeneca vaccine data supports its use as a booster shot

NAIROBI, Kenya Jan 14 – Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial have shown that the AstraZeneca COVID-19 vaccine, when given as a booster shot increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.

This follows a separate analysis of samples from the trial that showed increased antibody response to the Omicron variant.

The results were observed among individuals previously vaccinated with either AstraZeneca COVID-19 vaccine or an mRNA vaccine.

A separate Phase IV trial reported in a preprint with The Lancet on Social Science Research Network (SSRN) showed that a third dose of AstraZeneca substantially increased antibody levels following a primary vaccine series with CoronaVac (Sinovac Biotech).

“AstraZeneca Covid-19 vaccine has protected hundreds of millions of people from Covid-19 around the world and these data show that it has an important role to play as a third dose booster, including when used after other vaccines,” stated the BioPharmaceuticals R&D, AstraZeneca Executive Vice President Sir Mene Pangalos.

The data adds to the growing body of evidence supporting AstraZeneca as a third dose booster irrespective of the primary vaccination schedules tested.

“Given the ongoing urgency of the pandemic and AstraZeneca Covid-19 vaccine’s increased immune response to the Omicron variant, we will continue to progress regulatory submissions around the world for its use as a third dose booster,” said Pangalos

“The latest AstraZeneca Covid-19 vaccine data is of particular importance considering the spread of the Omicron variant. This is good news for Sub-Saharan Africa, where over 70 million doses of the AstraZeneca Covid-19 vaccine have been supplied, and where countries are striving to attain their vaccination targets and some are beginning to roll out booster programmes,” AstraZeneca Africa Country President Barbara Nel stated.

The D7220C00001 safety and immunogenicity trial showed that AstraZeneca Covid-19 vaccine continued to be generally well tolerated

Advertisement. Scroll to continue reading.

Further analyses from the trial are expected in the first half of 2022.

Previous studies done in the United Kingdom support AstraZeneca as a third dose booster as part of a homologous or heterologous schedule.

In a sub-analysis from the COV001 and COV002 trials, a third dose of AstraZeneca COVID-19 vaccine given at least six months after a second dose significantly boosted antibody levels and maintained T cell response.

It also resulted in higher neutralising activity against the Alpha, Beta, and Delta variants, compared with a two-dose regimen.

About The Author

Comments
Advertisement

More on Capital News

CHINA DAILY

Officials said the clusters were all caused by recognized pathogens and medical workers are dealing with them with mature treatment plans.

Capital Health

Since its inception in 2014, the programme has conducted over 38.5 million blood pressure screenings; and diagnosed over 3.1 million people.

Focus on China

The 31st International University Sports Federation (FISU) Summer World University Games officially opened in Chengdu, the capital of southwest China’s Sichuan Province, on Friday...

Top stories

NAIROBI, Kenya July 12 – The International Center for Research on Women (ICRW) has published two reports that shed light on the challenges Kenyan...

Africa

NAIROBI,Kenya, Jun 14 – Ugandan President Yoweri Museveni who is currently in isolation after contracting the Coronavirus (COVID-19) has told off Kenyans over claims...

World

UNITED NATIONS, May 17 (Xinhua) — The world economy faces the risk of a prolonged period of low growth as a result of legacy...

Focus on China

The claim that China concealed information on early coronavirus cases is not true, Zhou Lei, a researcher from the Chinese Center for Disease Control...

Top stories

NAIROBI, Kenya Mar 4 – Deputy President Rigathi Gachagua has said taxpayers’ money running into billions of shillings, including funds meant to deal with...